Attachment 6b
Surveillance Period Inpatient Form
OMB NO: 0920-0740
EXPIRATION DATE: 06/30/2010
Medical Monitoring Project (MMP)
Medical Record Abstraction Form
2008 Surveillance Period Inpatient Form (SPIF)
VERSION 3.0.0
Public reporting burden of this collection of information is estimated to average 3 minutes per patient record pulled, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC, Project Clearance Officer, 1600 Clifton Road, MS D-24, Atlanta, GA 30333, ATTN: PRA (0920-0011). Do not send the completed form to this address.
O PTIONAL- FOR LOCAL USE ONLY
MMP SPIF v3.0.0
MMP Participant ID:
Date of Admission: Date not documented
A bstraction Facility ID:
(ID of facility where abstraction is being conducted)
Inpatient medical record number:
Medical record number not documented
Patient name:
Patient residence:
Street:
City/County: State:
ZIP code:
Physician name:
|
DEPARTMENT OF HEALTH AND
HUMAN SERVICES Centers
for Disease Control & Prevention
M edical Monitoring Project (MMP)
Medical Record Abstraction Form
2008 Surveillance Period Inpatient Form (SPIF)
v3.0.0
I. ABSTRACTION AND IDENTIFICATION |
||||
MMP Participant ID: |
||||
Surveillance Period (SP)
SP start date:
(12 months prior to date of interview OR 1st contact attempt if no interview obtained) |
SP end date:
(date of interview OR 1st contact attempt if no interview obtained)
|
|||
Date of abstraction: |
Abstractor ID: |
|||
Date of admission:
Date not documented
|
Date of discharge:
Date not documented |
|||
Abstraction Facility ID:
(ID of facility where abstraction is being conducted)
|
|
|||
Was the documented care abstracted with this form given at another facility (i.e., outside the Abstraction Facility)?
|
||||
|
|
Yes Complete information about the “Care” Facility
|
Enter Care Facility ID or indicate that Care Facility was not documented or was outside jurisdiction
Care Facility ID
(ID of the facility where the documented care was provided) |
|
|
|
|
||
|
|
No Continue to Section II below |
Care Facility not documented or outside jurisdiction |
|
II. SURVEILLANCE PERIOD INPATIENT FORM SECTIONS – OPTIONAL |
||||
Is there documentation of any of the following during this inpatient stay? Yes Select all that are documented below. No This form is now complete except for optional section VIII (Remarks). |
||||
New or existing diagnoses of AIDS defining Opportunistic Illnesses (AIDS OI) Complete section III. |
Prescription or continuation of medications other than ART Complete section VI. |
|||
New or existing diagnoses of conditions other than AIDS OI Complete section IV. |
Laboratory test results, closest to admission Complete section VII. |
|||
Prescription or continuation of antiretroviral therapy (ART) closest to admission Complete section V. |
Laboratory test results, closest to discharge Complete section VII. |
|||
Prescription or continuation of antiretroviral therapy (ART) closest to discharge Complete section V. |
Laboratory test results, hepatitis screening tests Complete section VII. |
III. AIDS DEFINING OPPORTUNISTIC ILLNESSES (AIDS OI) |
||||
Is there documentation any new or existing diagnoses of AIDS defining opportunistic illnesses (AIDS OI) during this inpatient stay? Yes Select all that are documented below. No |
||||
1 Candidiasis, bronchi, trachea, or lungs |
14 Lymphoma, Burkitt’s (or equivalent term) |
|||
2 Candidiasis, esophageal |
15 Lymphoma, immunoblastic (IBL, or equivalent term) |
|||
3 Carcinoma, invasive cervical |
16 Lymphoma, primary in brain |
|||
4 Coccidioidomycosis, disseminated or extrapulmonary |
17 Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary |
|||
5 Cryptococcosis, extrapulmonary |
18 M. tuberculosis, pulmonary |
|||
6 Cryptosporidiosis, chronic intestinal (>1 month duration) |
19 M. tuberculosis, disseminated or extrapulmonary |
|||
7 Cytomegalovirus disease (other than in liver, spleen, or nodes) |
20 Mycobacterium, of other species or unidentified species, disseminated or extrapulmonary |
|||
8 Cytomegalovirus retinitis (with loss of vision) |
21 Pneumocystis jiroveci pneumonia (PCP) |
|||
9 Herpes simplex: chronic ulcer (>1 month duration) or bronchitis, pneumonitis, or esophagitis |
22 Pneumonia, recurrent in 12 month period |
|||
10 HIV encephalopathy |
23 Progressive multifocal leukoencephalopathy (PML) |
|||
11 Histoplasmosis, disseminated or extrapulmonary |
24 Salmonella septicemia, recurrent |
|||
12 Isosporiasis, chronic intestinal (>1 month duration) |
25 Toxoplasmosis of brain |
|||
13 Kaposi’s sarcoma |
26 Wasting syndrome due to HIV |
|||
IV. CONDITIONS OTHER THAN AIDS OI |
||||
Is there documentation of any new or existing diagnoses of conditions other than AIDS OI during this inpatient stay? Yes Select all that are documented below. No |
||||
1 Abscess |
19 Erythema multiforme |
37 Hypogonadism (gonadal deficiency) |
55 Prostatitis |
|
2 Alcoholism |
20 Erythroderma |
38 Hypothyroidism |
56 Psoriasis |
|
3 Anxiety disorder |
21 Fatty liver |
39 Ischemic heart disease |
57 Psychosis, including schizophrenia |
|
4 Arthritis (osteoarthritis) |
22 Fever, unexplained, >100F for 2+ weeks* |
40 Lactic acidosis |
58 Pulmonary hypertension |
|
5 Asthma |
23 Gastroesophageal reflux disease (GERD) |
41 Lipoatrophy |
59 Rash, drug-related |
|
6 Avascular necrosis |
24 Guillain-Barré syndrome |
42 Lipodystrophy |
60 Renal failure |
|
7 Buffalo hump |
25 Hearing loss, acquired |
43 Malignancy |
61 Respiratory infection, upper |
|
8 Bronchitis |
26 Hepatic (liver) failure |
44 Metabolic syndrome |
62 Respiratory infection, NOS |
|
9 Cardiomyopathy, due to HIV or unknown cause |
27 Hepatitis, alcohol-induced |
45 Myelopathy (spinal cord disease/disorder) |
63 Seborrheic dermatitis |
|
10 Cellulitis (skin infection, bacterial) |
28 Hepatitis, drug-induced |
46 Myopathy (muscular weakness or changes) |
64 Stevens-Johnson Syndrome |
|
11 Depression, diagnosed by physician |
29 Hepatitis, infectious, not drug-induced |
47 Nephrolithiasis (kidney stone) |
65 Stroke, ischemic, non- hemorrhagic |
|
12 Diabetes mellitus (DM), type 1 |
30 Hepatitis, NOS |
48 Nephropathy (kidney damage) |
66 Suicide attempt |
|
13 Diabetes mellitus (DM), type 2 |
31 Hodgkin’s lymphoma (Hodgkin’s disease) |
49 Neuropathy, cranial |
67 Thrombocytopenia, idiopathic (ITP) |
|
14 Diabetes mellitus (DM), NOS
|
32 Human papillomavirus (HPV) infection |
50 Neuropathy, peripheral |
68 Vision loss, moderate or severe; blindness |
|
15 Diarrhea, allergic/colitis |
33 Hypercholesterolemia |
51 Neuropathy, NOS |
69 Warts, anal or genital |
|
16 Diarrhea, infectious |
34 Hyperglycemia |
52 Oral candidiasis (thrush) |
70 Warts, non-anal, non- genital |
|
17 Diarrhea, NOS |
35 Hypertension (high blood pressure) |
53 Osteopenia or osteoporosis |
*in absence of a known cause |
|
18 Erectile dysfunction |
36 Hypertriglyceridemia |
54 Pneumonia |
|
IV. CONDITIONS OTHER THAN AIDS OI cont’d |
|||||
71 Other, specify:
|
|||||
72 Other, specify:
|
|||||
73 Other, specify:
|
|||||
74 Other, specify: |
|||||
75 Other, specify:
|
|||||
76 Other, specify: |
|||||
77 Other, specify: |
|||||
V. ANTIRETROVIRAL THERAPY (ART) |
|||||
Is there documentation of prescription of antiretroviral therapy (ART) during this inpatient stay? Yes Select all that are documented below. No |
|||||
Prescription or continuation closest to: |
|
||||
Admission |
Discharge |
Name |
Abbreviation |
Also Known As |
Group |
1 |
1 |
Abacavir |
ABC |
Ziagen |
NRTI |
2 |
2 |
Amprenavir |
APV |
Agenerase |
PI |
3 |
3 |
Atazanavir |
ATV |
Reyataz |
PI |
4 |
4 |
Atripla |
EFV/FTC/TDF |
|
Multi-class |
5 |
5 |
Combivir |
AZT/3TC |
|
CNRTI |
6 |
6 |
Darunavir |
DRV, TMC 114 |
Prezista |
PI |
7 |
7 |
Delavirdine |
DLV |
Rescriptor |
NNRTI |
8 |
8 |
Didanosine |
Ddl |
Videx |
NRTI |
9 |
9 |
Efavirenz |
EFV |
Sustiva |
NNRTI |
10 |
10 |
Emtricitabine |
FTC |
Emtriva |
NRTI |
11 |
11 |
Enfuvirtide |
ENF, T-20 |
Fuzeon |
FI |
12 |
12 |
Epzicom |
ABC/3TC |
|
CNRTI |
13 |
13 |
Etravirine (formerly TMC125) |
ETR |
Intelence |
NNRTI |
14 |
14 |
Fosamprenavir |
FPV |
Lexiva |
PI |
15 |
15 |
Indinavir |
IDV |
Crixivan |
PI |
16 |
16 |
Lamivudine |
3TC |
Epivir |
NRTI |
17 |
17 |
Lopinavir/Ritonavir |
LPV/RTV |
Kaletra, Meltrex |
CNRTI |
18 |
18 |
Maraviroc |
MRC |
Selzentry |
Entry inhibitor |
19 |
19 |
Nelfinavir |
NFV |
Viracept |
PI |
20 |
20 |
Nevirapine |
NVP |
Viramune |
NNRTI |
21 |
21 |
Raltegravir (formerly MK-0518) |
RAL |
Isentress |
Integrase inhibitor |
22 |
22 |
Ritonavir |
RTV |
Norvir |
PI |
23 |
23 |
Saquinavir |
SQV-HGC |
Invirase, Fortovase |
PI |
24 |
24 |
Stavudine |
d4T |
Zerit |
NRTI |
25 |
25 |
Tenofovir |
TDF |
Viread |
NRTI |
26 |
26 |
Tipranavir |
TPV |
Aptivus |
PI |
27 |
27 |
Trizivir |
ABC/3TC/AZT |
|
CNRTI |
28 |
28 |
Truvada |
FTC/TDF |
|
CNRTI |
V. ANTIRETROVIRAL THERAPY (ART) cont’d |
||||||||
Prescription or continuation closest to: |
|
|||||||
Admission |
Discharge |
Name |
Abbreviation |
Also Known As |
Group |
|||
29 |
29 |
Zalcitabine |
ddC |
Hivid |
NRTI |
|||
30 |
30 |
Zidovudine |
AZT |
Retrovir |
NRTI |
|||
31 |
31 |
Other, Specify: |
||||||
32 |
32 |
Other, Specify: |
||||||
33 |
33 |
Other, Specify: |
||||||
VI. OTHER MEDICATIONS |
||||||||
Is there documentation of prescription or continuation of medications other than ART during this inpatient stay? Yes Select all that are documented below. No |
||||||||
1 |
acarbose |
35 |
dapsone (DDS) |
|||||
2 |
acetominophen/hydrocodone |
36 |
darifenacin |
|||||
3 |
acetominophen/oxycodone |
37 |
dexamethasone |
|||||
4 |
acyclovir |
38 |
diphenhydramine |
|||||
5 |
adefovir |
39 |
doxorubicin |
|||||
6 |
albuterol |
40 |
doxorubicin lipsomal |
|||||
7 |
albuterol/ipratropium |
41 |
doxycycline |
|||||
8 |
aldesleukin |
42 |
dronabinol |
|||||
9 |
alprazolam |
43 |
enalapril |
|||||
10 |
amikacin |
44 |
enalapril/hydrochlorothiazide (HCTZ) |
|||||
11 |
amitriptyline |
45 |
entecavir |
|||||
12 |
amitriptyline/chlordiazepoxide |
46 |
epoetin alfa (EPO) |
|||||
13 |
amoxicillin |
47 |
escitalopram |
|||||
14 |
amoxicillin/clavulanate |
48 |
esomeprazole |
|||||
15 |
aspirin (ASA) |
49 |
ethambutol |
|||||
16 |
atenolol |
50 |
ethionamide |
|||||
17 |
atorvastatin |
51 |
famotidine |
|||||
18 |
azithromycin |
52 |
fexofenadine |
|||||
19 |
baclofen |
53 |
filgrastim |
|||||
20 |
bupropion |
54 |
folinic acid |
|||||
21 |
buspirone |
55 |
fluconazole |
|||||
22 |
butalbital/aspirin |
56 |
fludrocortisone |
|||||
23 |
butalbital/aspirin/caffeine (BAC) |
57 |
fluoxetine |
|||||
24 |
calcitrol |
58 |
fluphenazine |
|||||
25 |
capreomycin |
59 |
fluticasone |
|||||
26 |
cetirizine |
60 |
fluticasone/salmeterol |
|||||
27 |
chlorpropamide |
61 |
fluvastatin |
|||||
28 |
cimetidine |
62 |
foscarnet |
|||||
29 |
ciprofloxacin |
63 |
gabapentin |
|||||
30 |
citalopram |
64 |
gatifloxacin |
|||||
31 |
clonazepam |
65 |
gemfibrozil |
|||||
32 |
cromolyn |
66 |
hydrochlorothiazide (HCTZ) |
|||||
33 |
cycloserine |
67 |
hydrochlorothiazide (HCTZ)/methyldopa |
|||||
34 |
cyclosporine |
68 |
hydrochlorothiazide (HCTZ)/metoprolol |
VI. OTHER MEDICATIONS cont’d |
|||
69 |
hydrochlorothiazide (HCTZ)/triamterene |
108 |
penicillin |
70 |
imiquimod |
109 |
phenytoin |
71 |
insulin (inhaled or injectable) |
110 |
pioglitazone |
72 |
interferon alphacon-1 |
111 |
podofilox topical |
73 |
interferon alfa 2a |
112 |
podophyllin topical |
74 |
interferon alfa 2b |
113 |
pravastatin |
75 |
iodoquinol |
114 |
prednisone |
76 |
isoniazid (INH) |
115 |
propranolol |
77 |
isoniazid (INH)/pyrazinamide (PZA)/rifampin |
116 |
propranolol/hydrochlorothiazide (HCTZ) |
78 |
isoniazid (INH)/rifampin |
117 |
pyrazinamide (PZA) |
79 |
kanamycin |
118 |
ranitidine |
80 |
lansoprazole |
119 |
ribavirin |
81 |
lansoprazole/amoxicillin/clarithromycin |
120 |
rifabutin |
82 |
levofloxacin |
121 |
rifampin |
83 |
levothyroxine |
122 |
rifapentine |
84 |
lisinopril |
123 |
rosiglitazone |
85 |
lithium |
124 |
rosiglitazone/glemepiride |
86 |
loxapine |
125 |
rosuvastatin |
87 |
megestrol |
126 |
sertraline |
88 |
metformin |
127 |
sildenafil |
89 |
methadone |
128 |
somatropin |
90 |
metoclopramide |
129 |
streptomycin |
91 |
metoprolol |
130 |
tadalafil |
92 |
mirtazapine |
131 |
tamsulosin |
93 |
moxifloxacin |
132 |
telbivudine |
94 |
nalbuphine |
133 |
testosterone |
95 |
niacin |
134 |
tinidazole |
96 |
nifedipine |
135 |
trazadone |
97 |
nizatidine |
136 |
triamcinolone nasal |
98 |
octreotide |
137 |
trichloracetic acid (TCA) topical |
99 |
olanzapine |
138 |
trimethoprim/sulfamethoxazole (TMP/SMZ) |
100 |
omeprazole |
139 |
valacyclovir |
101 |
oxycodone |
140 |
valproic acid |
102 |
p-aminosalicylate |
141 |
vancomycin |
103 |
palonosetron |
142 |
vardenafil |
104 |
pantoprazole |
143 |
venlafaxine |
105 |
paroxetine |
144 |
warfarin |
106 |
peginterferon alfa 2a |
145 |
zanamivir |
107 |
peginterferon alfa 2b |
146 |
zolpidem |
147 Other, Specify: |
|||
148 Other, Specify: |
|||
149 Other, Specify: |
|||
150 Other, Specify: |
|||
151 Other, Specify: |
VII. INPATIENT LABORATORY TEST RESULTS |
|||||||||||||
Is there documentation of any of the following laboratory test results during this inpatient stay? Yes Enter all that are documented for each test below. No |
|||||||||||||
Laboratory tests performed closest to admission: (select all that are documented)
|
|||||||||||||
|
Result |
|
|||||||||||
Undetectable |
Value |
Units (select one, where applicable) |
|||||||||||
1 CD4 cell count |
|
|
Cells/ mm3 or µL
Other, specify: ___________________________ |
Units not documented |
|||||||||
2 CD4 cell % |
|
|
% |
|
|||||||||
3 HIV viral load |
|
|
Copies/mL
Other, specify: ___________________________ |
Units not documented |
|||||||||
|
Lower Limit of Detection for HIV Viral Load Test Used: Lower Limit of Detection NOT documented |
|
|||||||||||
4 ALT (SGPT) |
|
|
Units /L
Other, specify: ___________________________ |
Units not documented |
|||||||||
5 AST (SGOT) |
|
|
Units/L
Other, specify: ___________________________
|
Units not documented |
|||||||||
6 Creatinine (Creat, Cr) |
|
|
mg/dL
Other, specify: ___________________________
|
Units not documented |
|||||||||
Laboratory tests performed closest to discharge: (select all that are documented)
|
|||||||||||||
|
Result |
|
|||||||||||
Undetectable |
Value |
Units (select one, where applicable) |
|||||||||||
1 CD4 cell count |
|
|
Cells/ mm3 or µL
Other, specify: ___________________________ |
Units not documented |
|||||||||
2 CD4 cell % |
|
|
% |
|
|||||||||
3 HIV viral load |
|
|
Copies/mL
Other, specify: ___________________________ |
Units not documented |
|||||||||
|
Lower Limit of Detection for HIV Viral Load Test Used: Lower Limit of Detection NOT documented |
|
|||||||||||
4 ALT (SGPT) |
|
|
Units /L
Other, specify: ___________________________ |
Units not documented |
|||||||||
5 AST (SGOT) |
|
|
Units/L
Other, specify: ___________________________
|
Units not documented |
|||||||||
6 Creatinine (Creat, Cr) |
|
|
mg/dL
Other, specify: ___________________________
|
Units not documented |
|||||||||
INFECTIOUS DISEASE TESTS: Hepatitis A, B, C |
|||||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
|||||||
22 Anti-HAV IgG (HAV Ab IgG) |
|
|
|
|
|
|
|
|
|||||
23 Anti-HAV IgM (HAV Ab IgM) |
|
|
|
|
|
|
|
|
|||||
24 Anti-HAV total (HAV Ab total) |
|
|
|
|
|
|
|
|
VII. INPATIENT LABORATORY TEST RESULTS cont’d |
||||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
||||||
25 Anti-HBc IgG (HBc Ab IgG) |
|
|
|
|
|
|
|
|
||||
26 Anti-HBc IgM (HBc Ab IgM) |
|
|
|
|
|
|
|
|
||||
27 Anti-HBc total (HBc Ab total) |
|
|
|
|
|
|
|
|
||||
28 Anti-HBe (HBe Ab)
|
|
|
|
|
|
|
|
|
||||
29 Anti-HBs IgG (HBs IgG Ab)
|
|
|
|
|
|
|
|
|
||||
30 Anti-HBs total (HBs Ab) |
|
|
|
|
|
|
|
|
||||
31 HBeAg (Hepatitis B e-antigen) |
|
|
|
|
|
|
|
|
||||
32 HBsAg (Hepatitis B surface antigen) |
|
|
|
|
|
|
|
|
||||
33 HBV DNA (PCR) |
|
|
|
|
|
IU/mL
Other, specify: _______________________ |
Units not documented |
|||||
|
Lower Limit of Detection for HBV DNA (PCR) Test Used: |
|
||||||||||
Lower Limit of detection NOT documented |
||||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
||||||
34 Anti-HCV, EIA or RIBA |
|
|
|
|
|
|
|
|
||||
35 HCV genotype |
|
|
|
|
|
|
|
|
||||
36 HCV RNA qualitative |
|
|
|
|
|
|
|
|
||||
37 HCV RNA quantitative (PCR) |
|
|
|
|
|
IU/mL
Other, specify: _______________________ |
Units not documented |
|||||
|
Lower Limit of Detection for HCV RNA (PCR) Test Used: |
|
||||||||||
Lower Limit of Detection NOT documented |
MMP SPIF v3.0.0
Abstraction
MMP Participant ID: Facility ID:
(ID of facility where abstraction is being conducted)
Date of Admission:
Mo.
Day
Year
VIII. REMARKS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
File Type | application/msword |
File Title | Medical monitoring project (MMP) |
Author | Rita Morgan |
Last Modified By | ziy6 |
File Modified | 2009-02-26 |
File Created | 2009-02-26 |